Skip to main content

Table 4 Result of Y-randomization test of the selected model

From: In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line

Model R R2 Q2
Original 0.935611 0.875367 0.472886
Random 1 0.673207 0.453208 − 0.49528
Random 2 0.339829 0.115484 − 1.11468
Random 3 0.494563 0.244592 − 0.21047
Random 4 0.450413 0.202872 − 0.85992
Random 5 0.556608 0.309812 − 1.14735
Random 6 0.5238 0.274366 − 0.46273
Random 7 0.551894 0.304587 − 0.41126
Random 8 0.293835 0.086339 − 0.72515
Random 9 0.529202 0.280055 − 1.12015
Random 10 0.567466 0.322018 − 0.36167
Random models parameters    
Average R 0.498082   
Average R2 0.259333   
Average Q2 − 0.69087   
cRp2 0.741014